Abstract: Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described

Abstract: This invention provides a novel Cryptosporidium parvum protein disulfide isomerase polypeptide, and nucleic acids that encode this polypeptide. The invention also provides methods, reagents, and kits that are useful for diagnosing infection by Cryptosporidium parvum. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the protein disulfide isomerase polypeptide of C. parvum.

Abstract: A device and method are provided for percutaneous transdermal delivery of a immunologically active agent. The agent is mixed with appropriate surfactants and dissolved in water to form an aqueous coating solution having the appropriate concentration for coating extremely tiny skin piercing elements. The coating solution is applied to the skin piercing elements using known coating techniques and then dried. The device is applied to the skin of a living animal, causing the microprotrusions to pierce the stratum corneum and deliver a immunologically effective dose of the immunologically active agent to the animal.

Abstract: Isolated and purified peptides and variants thereof, as well as DNA encoding those peptides, useful to prevent or treat antibody inhibitors of factor VIII, are provided.

Abstract: The present invention provides substances suitable for use as vaccines for the prevention of EBV infection and EBV-associated disorders and methods for administering them. The vaccines are directed against HERV-K18 emv (SEQ ID:1) and most preferably comprise antigens obtained from HERV-K18 emv. Preferred antigens include SEQ ID:2, SEQ ID:3 and SEQ ID:4. Most preferably, the SAg T cell stimulatory activity of the HERV-K18 emv is diminished or eliminated. In another embodiment, the vaccine contains a nucleic acid encoding HERV-K18 emv or an immunogenic fragment thereof. The present invention also provides methods for treating EBV infection and EBV-associated disorders.

Abstract: The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. Immunization in-vivo via an intraperitoneal prime followed by intranasal or intragastric boosts with gp41HA induces high concentrations of serum IgG antibodies and fecal IgA antibodies that reacted with gp41 in HIV-1IIIB viral lysate and are cross-reactive with gp41 in HIV-1MN lysate. Follow up analyses by indirect immunofluorescence showed that both serum IgG and fecal IgA recognized human peripheral blood mononuclear cells infected with either syncytium-inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells.

Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human insulin to result in insulin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: The present invention is directed to a novel strain of feline immunodeficiency virus, designated herein as FIV-141, and to attenuated forms of the virus produced by mutating specific regions of the viral genome. The virus and mutated forms of the virus may be used to induce the production of antibodies to FIV-141, and in vaccines designed to protect cats from FIV.

Abstract: The present invention provides multivalent chimeric conjugate vaccine molecule and methods of using the conjugate to immunize subjects against bacterial infections. A conjugate molecule of the invention comprises multiple bacterial capsular polysaccharides linked to a carrier protein. Accordingly, the conjugate molecule provides immune protection against multiple types of bacteria in a single vaccines. In particular, conjugate molecules of the invention are used to prevent or attenuate Group B Streptococcus and meningococcal infections.

Abstract: Disclosed herein is a novel vaccine formulation for prophylatic or therapeutic immunization of vertebrates against infections caused by vertebrate viruses. The said vaccine contains a minimum of two components, one of which is a deoxyribonucleotide (DNA) vaccine comprising of a DNA molecule that encodes a polypeptide of the virus and the other component consisting of inactivated form of the virus. This invention can also be used to develop low cost inactivated virus-based vaccines that contain much lower amount of the said virus than that present in similar vaccines known in the prior art. This invention also relates to a process of producing that said novel vaccine formulation and the use of the said formulation.

Abstract: The invention relates to the use of an influenza antigen preparation obtainable by the following process, in the manufacture of an intradermal flu vaccine: (i) harvesting of virus-containing material from a culture; (ii) clarification of the harvested material to remove non-virus material; (iii) concentration of the harvested virus; (iv) a further step to separate whole virus from non-virus material; (v) splitting of the whole virus using a suitable splitting agent for instance a detergent such as sodim deoxycholate in a density gradient centrifugation step; (vi) filtration to remove undesired materials; wherein the steps are performed in that outer but not necessarily consecutively.

Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.

Abstract: The present invention describes a substance or a receptor comprising Helicobacter pylori binding oligosaccharide sequence [Gal(A)q(NAc)r/Glc(A)q(NAc)r&agr;3/&bgr;3]s[Gal&bgr;4GlcNAc&bgr;3]tGal&bgr;4Glc(NAc)u wherein q, r, s, t, and u are each independently 0 or 1, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori.

Abstract: The present invention relates to novel preparations for a broad-spectrum antiplasmodial vaccine that may contain a vaccinating antigen of Plasmodium falciparum capable of inducing resistance to the parasite and a kit containing the same. The invention relates to a method that may invoke the mechanisms of protective immunity and/or premonition.

Abstract: A method of treating tumors and other conditions in a patient is provided. The method involves administering to the patient a treatment medicament. The medicament contains a first component and a second component. The first component can be a quantity of tumor cells derived from the patient, and the second component is a quantity of annexin, preferably annexin V. The first component and second component are provided in a therapeutically effective treatment amount. Other conditions can also be treated with annexin.

Abstract: Stable emulsions comprising as a base one or more diene conjugated fatty acids. Amino acids and other macromolecules can be used to stabilize the emulsion. The emulsion is also useful as a carrier and delivery vehicle of the macromolecules to humans or animals in need of the macromolecules. Plant oil extracts, such as conjugated linoleic acid and its acylated derivatives, are useful as the diene conjugated fatty acids that form the base of the stable emulsion. The emulsions formed are useful as nutritional or cosmetic adjuvant for oral based nutrition, skin diseases, cosmetic utility, enhancing oral nutrition, or pharmacological benefit. Methods of producing and using the emulsions are also provided.

Abstract: Comb polymers are used as dispersants to increase the stability of colloidal suspensions containing multivalent or high concentrations of monovalent ions. Stabilized colloidal suspensions and methods of forming stabilized colloidal suspensions are described, including suspensions containing ceramic precursors or bioactive agents useful in forming ceramic substrates or pharmaceutical compositions, respectively.

Abstract: Disclosed is a cosmetic composition comprising: (a) a double coated pigment coated by a mixture of a fluorine coating compound and a silicone coating compound; (b) a light silicone oil having a viscosity of no more than about 60 mPas and a volatility as such that not more than 35% evaporates after standing at 150° C. at normal pressure for 24 hours; and (c) a gelling agent.

Abstract: A fixing agent in the form of an oil/water type, lamellar emulsion or suspension in which the aqueous phase is the principal component, the aqueous phase containing water and a byproduct of agriculture or fermentation and the oil phase containing oil and emulsifiers. The emulsion or suspension is prepared by adding an aqueous solution to the oil phase in order to produce a water/oil type emulsion or suspension, by adding a portion of the aqueous phase in order to produce an inverse oil/water type emulsion or suspension, and by thereafter mixing the oil/water type emulsion or suspension with the remainder of the aqueous phase.

Abstract: A physiologically acceptable composition, such as a cosmetic composition, comprising a continuous liquid fatty phase, which is gelled or thickened with at least one fatty acid ester of dextrin with a degree of substitution of less than 2, wherein the at least one fatty acid ester of dextrin makes it possible to obtain, for example, a stick that does not exude, and which gives a glossy, non-migrating and long-lasting deposit over time when applied.

Abstract: Cosmetic composition comprising rigid, substantially rectilinear fibres of a synthetic polymer in a physiologically acceptable medium, in which the polymer is chosen from polyurethanes, polyesters, acrylic polymers, polyolefins, non-aromatic polyamides and aromatic polyimide-amides.

Abstract: The present invention relates to improved hair styling compositions and methods of using such compositions. More particularly, the present invention relates to hair styling compositions with improved durability performance of the hair fixative resins, including resistance to high humidity, low tackiness, and good hold.

Abstract: A calcium phosphate-synthetic resin composite body produced by pressing a calcium phosphate block (or a calcium phosphate block and calcium phosphate particles), and synthetic resin particles I, which are at least partially cross-linked in advance, and uncross-linked, synthetic resin particles II while heating, the calcium phosphate block being exposed on at least part of the surface of the composite body. The above composite body is produced by a method comprising the steps of (a) introducing the calcium phosphate block (or a calcium phosphate block and calcium phosphate particles), the synthetic resin particles I and II into a cavity of a forming die such that the calcium phosphate block is present on at least part of the surface of the composite body, and that the synthetic resin particles surround the calcium phosphate particles, if any; and (b) pressing them in the cavity of the forming die while heating, so that the synthetic resin particles are bonded to each other.

Abstract: The invention provides therapeutic devices comprising a polymeric anti-inflammatory agent that biodegrades to release anti-inflammatory agents. The therapeutic devices are useful for repair and regeneration of a variety of injured tissues.

Abstract: A drug delivery system comprising a contact lens having dispersed therein as nanoparticles having a particle size less than about 50 nm, an ophthalmic drug nanoencapsulated in a material from which said ophthalmic drug is capable of diffusion into and migration through said contact lens and into the post-lens tear film when said contact lens is placed on the eye.

Abstract: A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. A method of production of the composition; use of the composition in the manufacture of a medicament; and a method of treatment of impaired gastro-intestinal tract function are described.

Abstract: An improved ultra-high fiber supplement that promotes satiety, caloric reduction, and weight loss. The supplement comprises guar, oat, psyllium, locust bean gum, pectin, green tea, multi-anthocyanadins, pyridoxine, and folic acid. It improves cardiovascular health and reduces cardiovascular inflammation and the risk of heart disease. The addition of antioxidants, including green tea, improves weight loss, and general and cardiovascular health. Also it reduces serum lipoprotein oxidation and risk of free-radical related diseases. Additional benefits include the lowering of plasma homocysteine by the addition of folic acid and pyridoxine. Consumption of the supplement aids in reducing absorption and assimilation of ingested toxins. A method of providing an ultra-high fiber comestible that is highly palatable and can be used to supplement nutrition and to manage and prevent diet-related diseases is disclosed.

Abstract: Animal feed compositions comprising amounts of protein, carbohydrate, fat and a functional ingredient for preventing hairball formation are provided.

Abstract: Animal feed compositions comprising amounts of protein, carbohydrate, fat and a functional ingredient for preventing hairball formation are provided. The functional ingredient comprises an electrostatically charge ingredient, preferably selected from the group consisting of electrostatically charged proteins, amino acids, conjugated proteins, dipeptides, multipeptides, protein colloids, enzymes, protein hydrolysates, natural and artificial food additives, flavorings, seasonings, and mixtures thereof.

Abstract: Neutral alpha amino diacid complexes of trace minerals and their use for animal nutrition.

Abstract: A method of making a wet roll includes providing a body of a roll of wet wound sheet material, where the body of the roll is connected to a tail of the roll, applying an adhesion promoter between the body and the tail, and contacting the body and the tail. The body and tail of the roll contain a wetting solution.

Abstract: Disclosed are methods products such as wet wipes and absorbents capable of providing a skin health benefit when utilized in the intended fashion. More specifically, the products described herein comprise an antioxidant agent, such as a botanical extract, which is capable of reducing the amount of oxidation on the skin's surface resulting in improved skin health. The antioxidant agent has an antioxidant potential at three minutes of at least about 25% as determined by a AST Antioxidant Status Test set forth herein. In another embodiment, the antioxidant agent has an antioxidant potential at thirty minutes of at least about 20% as determined by a AST Antioxidant Status Test set forth herein.

Abstract: Disclosed are methods and products such as wet wipes and absorbents capable of providing a skin health benefit when utilized in the intended fashion. More specifically, the products described herein comprise an agent, such as a botanical extract, which is capable of increasing the activity of sphingomyelinase according to a Sphingomyelinase Activity Screening Test and/or decreasing the activity of ceramidase according to a Ceramidase Activity Screening Test. By increasing the activity of sphingomyelinase and/or decreasing the activity of ceramidase, the agents in combination with the products described herein are able to maintain or increase the level of ceramides in the skin leading to improved skin health.

Abstract: Economical and improved pull apart fragrance sampling device constructed of a film to film laminate. The mechanism for release of fragrance is accomplished by providing a microcapsule layer between a top ply and a bottom ply, which upon drying holds the overlying plies together, the microcapsules rupture upon peeling the top ply from the bottom ply, the fragrance is thereby released. A sampler produced as disclosed provides greater stability and shelf life than a paper sampler product while dramatically reducing manufacturing and raw material costs due to it's construction. The sampler provides the maximum flexibility in use and manufacture at a minimum cost.

Abstract: A method and composition for treating healed wounds including hypertrophic scars so as to prevent scarring or reduce the size and improve the appearance of scars comprises applying to the healed wound or scar a composition comprising a fluid, film-forming carrier which may contain one or more active topical ingredients, the carrier hardening to a solid, tangible, membrane juxtaposed to the skin. Novel compositions using the film-forming carrier are also useful to treat a variety of adverse skin disorders, and internal physiological conditions.

Abstract: An adhesive bandage for the treatment of warts on the human skin is provided, comprising an upper layer of polyethylene coated cloth having a color and texture resembling a conventional bandage and visible upon application to the skin, the upper layer further including a center section and at least one side portion extending from the center section; and a lower layer permanently bonded to and coextending with the center section and the side portion, the lower layer having a rubber-based, waterproof, and nonbreathable adhesive material. The rubber-based adhesive material includes adhesive qualities identical in all respects to that of conventional duct tape. Optionally, the rubber-based adhesive material may be present only directly beneath the center section, while a skin-releasable adhesive material is present only directly beneath the side portion. A method of using the bandage for the treatment of warts is also provided.

Abstract: The present invention relates to a skin-friendly adhesive. According to the invention, the adhesive contains a substance which lowers the pH on contact with skin moisture. The invention also relates to a wound dressing which is provided with such an adhesive.

Abstract: The invention relates to transdermal therapeutic systems which have the active ingredient nicotine and have particularly high flexibility. This flexibility decisively improves wearer comfort on the skin, since the system is readily capable of adapting to the surface of the skin and its constant movement. Surprisingly, the nicotine TTS of the invention is markedly more flexible than the conventional nicotine TTS products which are leaders in the market, although at least some of those systems are comparably thin.

Abstract: A patch agent of the present invention comprises a support, and an adhesive layer laid on the support and containing an adhesive base and a drug, wherein the adhesive base contains an acrylic polymer substantially having no carboxyl and no hydroxyl in molecules thereof, and a rubber-based polymer, so as to achieve sufficiently high skin permeability of the drug and preparation properties. Accordingly, the present invention enables administration of the drug through skin to be implemented with drug administration effect at a sufficiently high level and on a stable basis.

Abstract: Cicatrizant hydrocolloidal patch comprising:

Abstract: There is provided an emulsion composition for therapeutic administration comprising: (a) at least one mono-electron transfer agent phosphate derivative; (b) at leas tone di-electron transfer agent phosphate derivative; wherein the amount of transfer agent phosphate derivatives is no less than equimolar to the amount of di-electron transfer agent phosphate; and (c) a suitable carrier.

Abstract: A new pharmaceutical composition in the form of lipoglobules which comprises (a) one or more NO-releasing NSAID(s); (b) one or more surfactant(s); and (c) an aqueous phase, as well as a process for the preparation of such composition and the use of such composition in the treatment of pain and inflammation.

Abstract: A tablet production apparatus comprising a gas generator G, a lubricant powder discharge means 51 for discharging a lubricant powder into a gas generated from the gas generator G, depending on the supply of the gas from the gas generator G, and mixing the lubricant powder with the gas in dispersed state, a lubricant application means 91 for spraying the lubricant powder discharged from the lubricant powder discharge means 51 and mixed with the gas generated from the gas generation means G in dispersed state, onto each material contacting surface of a die, an upper punch and a lower punch, and an oxygen concentration measuring means 131a for measuring the oxygen concentration of the gas existing near the lubricant application means 91. The apparatus is designed such that the amount of the gas supplied into the lubricant application means is adjusted based on the oxygen concentration measured by the oxygen concentration measuring means 131a.

Abstract: Sustained release pharmaceutical compositions comprising at least a cephalosporin antibiotic, a mixture of polymers comprising of galactomannans and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises about 30% to about 90% by weight of a cephalosporin antibiotic; about 1% to about 30% by weight of said mixture of polymers comprising from about 0.1% to about 15% by weight of galactomannans, and about 0.1% to about 15% of neutral swellable polymer by weight of sustained release composition.

Abstract: Methods are disclosed for forming a solid pharmaceutical composition having a desired release profile that include selecting hydroxypropylmethyl cellulose having a particular particle distribution to obtain the desired release profile, and forming a solid pharmaceutical composition comprising a core that comprises a bio-active and the hydroxypropylmethyl cellulose. Solid pharmaceutical compositions are also disclosed that include a bio-active, and hydroxypropylmethyl cellulose having a particle size that is selected to obtain a desired release profile.

Abstract: A solid oral delivery system having improved sustained release properties made of at least one lipid, dry particles including at least one pharmaceutical, and at least one filler, wherein the dry particles are continuously coated by the lipid and form a homogeneous suspension with the lipid, wherein the suspension, when melted, exhibits thixotropic and/or pseudoplastic properties, wherein the suspension is formed into the desired dose by molding or pouring the suspension when in a liquid or semi-liquid state. The process for preparing the present delivery system by melting the lipid, blending the dry particles which include the pharmaceutical, at least one filler and, optionally, flavorings with the melted lipid, and pouring or molding the suspension to provide the solid dose, wherein the suspension, when melted, exhibits thixotropic and pseudoplastic flow properties.

Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “g12h” (i.e., every 12 hour) administration through steady-state conditions.

Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.

Abstract: Tamsulosin pellets having an advantageous release profile are formed. The pellets have an enteric coating and release less than 10% of the tamsulosin in two hours in SGF.